Technophage , founding partner of Lxbio Pharmaceuticals,  has attended to ECCMID 2023. Together with the clinical team from Israel, it was presented the results obtained in the Phase I/IIa, aimed to determine the safety and tolerability of multiple doses of TP-102 in subjects with uninfected and infected diabetic foot ulcers. It has been successfully concluded and the company is now preparing the next clinical phases.

​

– Case study 1 showed a methicillin-resistant Staphylococcus aureus infection persisting for 12 month that failed to respond to repeated debridement and antibiotic treatment.

​

– Case study 2 showed an acute osteomyelitis that was developed while on antibiotic treatment.

​

Local application of TP-102 together with standard of care lead to an improved outcome of these complicated diabetic foot infections and complete resolution after long-term follow-up.

​

TP-102 is being developed for the treatment of infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Phase I/IIa has been successfully concluded and the company is now preparing the next clinical phases.

​

LxBio will be responsible for the production and worldwide commercialization of TP102.

​

For access to the full presentation please follow the link: (https://www.linkedin.com/feed/update/urn:li:activity:7061388008482123776). The presentation contains clinical images that may be harmful or traumatizing to some sensitive people.